irinotecan has been researched along with Carcinoma, Transitional Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Mathew Thomas, V; Swami, U; Tripathi, N | 1 |
| Bhattacharyya, M; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW | 1 |
| Shimizu, Y | 1 |
2 review(s) available for irinotecan and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Diarrhea; Humans; Immunoconjugates; Irinotecan; Neutropenia; Urinary Bladder Neoplasms | 2022 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
2 trial(s) available for irinotecan and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms | 2008 |